RxDoctor Payments Data

Majid Basit, MD

Interventional Cardiology · Sugar Land, TXNPI 1609078112

Payments from drug & device makers

$56,025in general payments, 2019–2025

Across 332 payments — averaging $168.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$35K
  • Medtronic$5K
  • Abbott$5K
  • Boston Scientific$2K
  • Amgen$2K
  • Boehringer Ingelheim$1K
  • plus $6K from 25 others

What the payments were for

  • Speaking & faculty fees$34,15061%
  • Travel & lodging$9,56317%
  • Food & beverage$12,21722%
  • Education$950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,025 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$356,659
Medicare patients
702
Services billed
3,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban455$551,403
Repatha SureclickEvolocumab309$336,392
XareltoRivaroxaban172$200,501
BrilintaTicagrelor100$104,215
EntrestoSacubitril/Valsartan42$69,134
JardianceEmpagliflozin62$53,820
Praluent PenAlirocumab22$28,442
Nifedipine ErNifedipine271$10,564
Clonidine66$8,324
Colesevelam Hcl13$8,273
Metoprolol Succinate356$7,237
Ranolazine ErRanolazine49$6,296
Rosuvastatin Calcium414$6,139
Flecainide Acetate137$5,697
Losartan Potassium496$5,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$551,403455 claims
Johnson & JohnsonXarelto$343$200,501172 claims
AstraZenecaBrilinta$35,436$104,215100 claims
NovartisEntresto$613$69,13442 claims
Boehringer IngelheimJardiance$1,014$53,82062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →